Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 17/20 | 0.59 |
| ▸ | GSK3B | P49841 | 16/20 | 0.59 |
| ▸ | WNT1 | P04628 | 13/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23741126 | 0.81 | DYRK1A (0.56) | DYRK1AGSK3BWNT1KDM4EALDH1A1 | |
| SCHEMBL23741354 | 0.80 | GSK3B (0.59) | DYRK1AGSK3BWNT1 | |
| SCHEMBL23740987 | 0.79 | DYRK1A (0.58) | DYRK1AGSK3BWNT1KDM4EALDH1A1 | |
| SCHEMBL23740834 | 0.79 | DYRK1A (0.58) | DYRK1AGSK3BWNT1KDM4EALDH1A1 | |
| SCHEMBL23741162 | 0.76 | DYRK1A (0.57) | DYRK1AGSK3BWNT1KDM4EALDH1A1 | |
| SCHEMBL19515504 | 0.74 | GSK3B (1.00) | DYRK1AGSK3BWNT1 | |
| SCHEMBL30005400 | 0.74 | GSK3B (1.00) | DYRK1AGSK3BWNT1 | |
| SCHEMBL20938541 | 0.74 | GSK3B (0.57) | DYRK1AGSK3BWNT1 | |
| SCHEMBL23740978 | 0.74 | GSK3B (0.62) | DYRK1AGSK3BWNT1 | |
| SCHEMBL23916195 | 0.74 | HCAR3 (0.36) | DYRK1AGSK3BWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3448838-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2021-08-11 | — | — | EP | disclosed |